{"id":309184,"date":"2024-03-24T15:43:16","date_gmt":"2024-03-24T20:43:16","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=309184"},"modified":"2024-03-22T17:30:21","modified_gmt":"2024-03-22T22:30:21","slug":"supreme-court-oral-arguments-abortion-pill-case","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/supreme-court-oral-arguments-abortion-pill-case\/","title":{"rendered":"Supreme Court to hear oral arguments in abortion pill case this week"},"content":{"rendered":"
<\/div>

(Liberty Counsel<\/a>) The U.S. Supreme Court will\u00a0hear<\/a>\u00a0oral arguments on Tuesday, March 26, in\u00a0U.S. Food and Drug Administration v. Alliance for Hippocratic Medicine<\/i>,\u00a0<\/i>along with\u00a0Danco Laboratories v. Alliance for Hippocratic Medicine<\/i>, regarding the FDA\u2019s approval of the chemical abortion drug Mifepristone, half of a two-drug protocol used to end pregnancies in early stages.<\/p>\n

The questions for discussion\u00a0presented<\/a>\u00a0are:<\/p>\n

1. Whether an association can demonstrate Article III standing to enjoin a government action by arguing that some unspecified member may be injured at some future time by the challenged action;<\/p>\n

2. Whether the Fifth Circuit erred in upholding the preliminary injunction of FDA\u2019s 2016 and 2021 actions based on the court\u2019s review of an incomplete administrative record.<\/p>\n

The FDA initially approved the drug in 2000, and in 2016 and 2021 it made several changes including allowing the drug to be used through the 10th week of pregnancy, rather than only through the 7th week, allowing healthcare providers who are not physicians to prescribe the drugs, and allowing the drug to be prescribed through telehealth appointments and sent through the mail. A group of doctors and medical groups have challenged the FDA\u2019s removal of critical safeguards allowing near-unfettered access to Mifepristone despite the drug\u2019s questionable safety\u00a0record<\/a>.<\/p>\n

In September 2023, the U.S. Fifth Circuit Court of Appeals placed restrictions on the distribution of Mifepristone after\u00a0determining<\/a>\u00a0that the FDA violated federal law, ignored science, and failed to put the health and safety of women first while placing and keeping the drug on the market. The FDA and Danco, which manufactures Mifepristone, have asked the U.S. Supreme Court to review the Fifth Circuit\u2019s decision.<\/p>\n

According to the latest study produced by the pro-abortion Guttmacher Institute, chemical abortions\u00a0accounted<\/a>\u00a0for 63 percent of all abortions in 2023. That is 642,700 of the estimated 1,026,690 abortions tracked by the U.S. health care system last year, an increase from 53 percent in 2020.<\/p>\n